Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with ...

An LED-based intraoral device for photobiomodulation therapy was safe and reduced severe oral mucositis in patients with head ...

The REMS program for vandetanib in the treatment of patients with medullary thyroid cancer has been removed by the FDA.

Leaders in oncology nursing and advanced practice spotlight the essential role of advanced practice providers in oncology.

BC, AOCNP, explains how ctDNA can inform prognosis, monitor disease progression, and guide treatment decisions in oncology.

Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.

The NCCN has added revumenib (Revuforj) to its guidelines for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) harboring NPM1 mutations, accordin ...